Bioorganic & Medicinal Chemistry Letters · 2023 · 11 citations · 23 references
PharmacyMedicinal ChemistryPharmacologyBioisosterismDrug DiscoveryEnzymologyCatalytic MechanismsEnzyme FunctionEnzyme InhibitionEnzyme KineticsEnzyme-substrate RecognitionLigand BindingBiomolecular Binding AffinityCoenzyme-dependent Enzyme ComplexesEnzyme Inhibitor DiscoveryEsterase-mediated HydrolysisOncogenic TransformationRate LimitingRate-limiting EnzymesThiamine Pyrophosphate Catalysis
Pyruvate dehydrogenase complex (PDHc) is suppressed in some cancer types but overexpressed in others. To understand its contrasting oncogenic roles, there is a need for selective PDHc inhibitors. Its E1-subunit (PDH E1) is a thiamine pyrophosphate (TPP)-dependent enzyme and catalyses the first and rate-limiting step of the complex. In a recent study, we reported a series of ester-based thiamine analogues as selective TPP-competitive PDH E1 inhibitors with low nanomolar affinity. However, when the ester linker was replaced with an amide for stability reasons, the binding affinity was significantly reduced. In this study, we show that an amino-oxetane bioisostere of the amide improves the affinity and maintains stability towards esterase-catalysed hydrolysis.
23
Metabolic Heterogeneity in Human Lung Tumors
Christopher T. Hensley, Brandon Faubert, Qing Yuan et al. · Cell · 2016 · 1.1K citations · Full text
Medicine, Cancer Biology, Oncology +14
Prodrugs of Phosphates and Phosphonates
Scott J. Hecker, Mark D. Erion · Journal of Medicinal Chemistry · 2008 · 412 citations